386 related articles for article (PubMed ID: 15161435)
81. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
van den Bogaert DP; Pouw EM; van Wijhe G; Vernhout RM; Surmont VF; Hoogsteden HC; van Klaveren RJ
J Thorac Oncol; 2006 Jan; 1(1):25-30. PubMed ID: 17409823
[TBL] [Abstract][Full Text] [Related]
82. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany.
Reck M; Stahel RA; von Pawel J; Karthaus M; Korfee S; Serke M; Schuette WH; Eschbach C; Fink TH; Leschinger MI; Manegold C
Respir Med; 2010 Jan; 104(1):142-8. PubMed ID: 19818589
[TBL] [Abstract][Full Text] [Related]
83. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
[TBL] [Abstract][Full Text] [Related]
84. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option?
Li L; Razak AR; Hughes A
Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592
[TBL] [Abstract][Full Text] [Related]
85. Pemetrexed in advanced NSCLC: a review of the clinical data.
Zinner RG; Fossella FV; Herbst RS
Oncology (Williston Park); 2004 Jul; 18(8 Suppl 5):54-62. PubMed ID: 15339061
[TBL] [Abstract][Full Text] [Related]
86. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
[TBL] [Abstract][Full Text] [Related]
87. The potential role of pemetrexed in gastrointestinal cancer.
Meriggi F; Di Biasi B; Caliolo C; Zaniboni A
Chemotherapy; 2008; 54(1):1-8. PubMed ID: 18063861
[TBL] [Abstract][Full Text] [Related]
88. Pemetrexed re-challenge in pleural malignant mesothelioma: an option for a subset of patients initially treated with pemetrexed-platinum doublets in the first-line setting?
Zalcman G; Bergot E; Lechapt E
Lung Cancer; 2011 Apr; 72(1):1-2. PubMed ID: 21277041
[No Abstract] [Full Text] [Related]
89. Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy?
Tamura K; Fujiwara Y
Asia Pac J Clin Oncol; 2010 Dec; 6(4):248-50. PubMed ID: 21114772
[No Abstract] [Full Text] [Related]
90. New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma.
Zucali PA; Giovannetti E; Assaraf YG; Ceresoli GL; Peters GJ; Santoro A
Ann Oncol; 2010 Jul; 21(7):1560-1561. PubMed ID: 20447928
[No Abstract] [Full Text] [Related]
91. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
Green J; Dundar Y; Dodd S; Dickson R; Walley T
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD005574. PubMed ID: 17253564
[TBL] [Abstract][Full Text] [Related]
92. Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
Lustgarten DE; Deshpande C; Aggarwal C; Wang LC; Saloura V; Vachani A; Wang LP; Litzky L; Feldman M; Creaney J; Nowak AK; Langer C; Inghilleri S; Stella G; Albelda SM
J Thorac Oncol; 2013 Apr; 8(4):469-77. PubMed ID: 23486267
[TBL] [Abstract][Full Text] [Related]
93. [Second-line treatment of malignant pleural mesothelioma with Pemetrexed (Alimta) -- a case report].
Nagel S; Hobrack E; Jehle P; Schütte W
Pneumologie; 2005 Feb; 59(2):108-11. PubMed ID: 15724224
[TBL] [Abstract][Full Text] [Related]
94. The issue of studies evaluating biomarkers which predict outcome after pemetrexed-based chemotherapy in malignant pleural mesothelioma.
Mairinger F; Vollbrecht C; Mairinger T; Popper H
J Thorac Oncol; 2013 Aug; 8(8):e80-2. PubMed ID: 23857409
[No Abstract] [Full Text] [Related]
95. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
Hayashi H; Okamoto I; Ichikawa Y; Miyazaki M; Yoshioka H; Kunimasa K; Nakagawa K
Int J Clin Oncol; 2010 Oct; 15(5):497-9. PubMed ID: 20224880
[TBL] [Abstract][Full Text] [Related]
96. Dramatic tumour response to pemetrexed single-agent in an elderly patient with malignant peritoneal mesothelioma: a case report.
Fasola G; Puglisi F; Follador A; Aita M; Di Terlizzi S; Belvedere O
BMC Cancer; 2006 Dec; 6():289. PubMed ID: 17176466
[TBL] [Abstract][Full Text] [Related]
97. Current chemotherapeutic treatment of malignant pleural mesothelioma.
Nowak AK; Byrne MJ; Millward MJ; Alvarez JM; Robinson BW
Expert Opin Pharmacother; 2004 Dec; 5(12):2441-9. PubMed ID: 15571462
[TBL] [Abstract][Full Text] [Related]
98. Pemetrexed and its emerging role in the treatment of thoracic malignancies.
Scagliotti GV; Novello S
Expert Opin Investig Drugs; 2003 May; 12(5):853-63. PubMed ID: 12720495
[TBL] [Abstract][Full Text] [Related]
99. Multimodality therapy in mesothelioma: role of chemotherapy.
Vogelzang NJ
Thorac Surg Clin; 2004 Nov; 14(4):531-42. PubMed ID: 15559060
[TBL] [Abstract][Full Text] [Related]
100. MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions.
Calvert H
Semin Oncol; 1999 Apr; 26(2 Suppl 6):105-8. PubMed ID: 10598564
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
